A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients
Ramanathan R, Weiss G, Posner R, Rajeshkumar N, Jameson G, Aziz M, Hoering A, Bolejack V, Maitra A, Fulk M, Stites E, Hlavacek W, Gatalica Z, Xiu J, Hidalgo M, Von Hoff D, Barrett M. A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients. Journal Of Gastrointestinal Oncology 2017, 8: 925-935. PMID: 29299351, PMCID: PMC5750179, DOI: 10.21037/jgo.2017.09.05.Peer-Reviewed Original ResearchMetastatic pancreatic cancer patientsPancreatic cancer patientsCancer patientsNon-cross-resistant regimensExcision repair cross-complementation group 1 proteinPhase II studyPhase 2 trialEfficacy of therapyBased treatment strategiesImmunohistochemistry targetingInsufficient tumorStudy therapyLine therapyMedian survivalCytotoxic therapyMetastatic lesionsCancer related symptomsTumor biopsiesII studyPercutaneous biopsyTumor immunohistochemistryTreatment regimensTreatment strategiesBiopsyRegimens